Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities, calculated as total liabilities divided by total asset. Diagnamed Holdings's Total Liabilities for the quarter that ended in Jun. 2026 was $0.36 Mil. Diagnamed Holdings's Total Assets for the quarter that ended in Jun. 2026 was $0.24 Mil.
Therefore, Diagnamed Holdings's Liabilities-to-Assets Ratio for the quarter that ended in Jun. 2026 was 1.54.
Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities. It can vary greatly across different industries, as they have different capital structure. A high Liabilities-to-Assets ratio (more leveraged) suggests that the company might have potential solvency problems, or even a signal of financial distress. Conversely, a low Liabilities-to-Assets ratio usually indicates a healthy financial situation. However, it may also suggest that the company is not expanding or not making good use of debt.
Diagnamed Holdings Liabilities-to-Assets Related Terms
Diagnamed Holdings Liabilities-to-Assets Historical Data
* Premium members only.
The historical data trend for Diagnamed Holdings's Liabilities-to-Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DGNMF vs VEEV, BTSG, HQY: Liabilities-to-Assets Comparison
For the Health Information Services subindustry, Diagnamed Holdings's Liabilities-to-Assets, along with its competitors' market caps and Liabilities-to-Assets data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Diagnamed Holdings Liabilities-to-Assets vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Diagnamed Holdings's Liabilities-to-Assets distribution charts can be found below:
* The bar in red indicates where Diagnamed Holdings's Liabilities-to-Assets falls into.
Liabilities-to-Assets ratio measures the portion of the total liabilities to the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Liabilities-to-Assets ratio is calculated by dividing total liabilities by total asset.
Diagnamed Holdings's Liabilities-to-Assets Ratio for the fiscal year that ended in Sep. 2025 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Diagnamed Holdings (DGNMF) has a Liabilities-to-Assets of 1.54 as of Jun. 2026. Liabilities-to-Assets equals total liabilities divided by total assets. It measures financial leverage. View historical data on Diagnamed Holdings and its competitors.
Is Diagnamed Holdings' Liabilities-to-Assets too high?
Diagnamed Holdings' current Liabilities-to-Assets is 1.54.
How does Diagnamed Holdings' Liabilities-to-Assets compare to VEEV and BTSG?
Diagnamed Holdings' Liabilities-to-Assets of 1.54 can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Liabilities-to-Assets for a Healthcare Providers & Services company?
A good Liabilities-to-Assets depends on the Healthcare Providers & Services industry context. However, Liabilities-to-Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Liabilities-to-Assets mean?
A high Liabilities-to-Assets can signal that a stock is expensive relative to its fundamentals. Liabilities-to-Assets equals total liabilities divided by total assets. It measures financial leverage. View historical data on Diagnamed Holdings and its competitors. Diagnamed Holdings's current Liabilities-to-Assets is 1.54. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Diagnamed Holdings stock overvalued right now?
Diagnamed Holdings (DGNMF) has a current Liabilities-to-Assets of 1.54. The current Liabilities-to-Assets is 1.54. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Liabilities-to-Assets calculated?
Liabilities-to-Assets is calculated from a company's financial statements. For Diagnamed Holdings (DGNMF), the current Liabilities-to-Assets is 1.54 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Diagnamed Holdings Corp is engaged in developing a platform of software-based prescription digital therapeutic products (PDT Products) with the potential to improve early detection of neurological disorders, overall patient health and lower healthcare costs. Its products include, CERVAI which is a brain health AI platform leveraging that aims to predict and monitor brain age and provide actionable insights for mental health and neurodegenerative disorders. It is also investigating other technological applications such as BrainAge and BrainTremor.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DGNMF has been successfully added to your 
